METHODS:
We conducted a prespecified substudy of a randomized controlled trial involving patients undergoing cardiac surgery with cardiopulmonary bypass (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) ; patients were recruited from 79 centres in 18 countries. Eligibility criter ia included a moderate-to-high risk of perioperative death based on a preoperative score of 6 or greater on the European System for Cardiac Operative Risk Evaluation I. Patients (n = 7286) were randomly assigned (1:1) to receive intravenous methylprednisolone (250 mg at anesthetic induction and 250 mg at initiation of cardiopulmonary bypass) or placebo. Patients, caregivers, data collectors and outcome adjudicators were unaware of the assigned intervention. The primary outcome was postoperative acute kidney injury, defined as an increase in the serum creatinine concentration (from the preoperative value) of 0.3 mg/dL or greater (≥ 26.5 µmol/L) or 50% or greater in the 14-day period after surgery, or use of dialysis within 30 days after surgery.
RESULTS:
Acute kidney injury occurred in 1479/3647 patients (40.6%) in the methylprednisolone group and in 1426/3639 patients (39.2%) in the placebo group (adjusted relative risk 1.04, 95% confidence interval 0.96 to 1.11) . Results were consistent across several definitions of acute kidney injury and in patients with preoperative chronic kidney disease.
Acute kidney injury substudy
The original protocol for this substudy was published previously (minor changes are summarized in Appendix 1, available at www. cmaj.ca/lookup/suppl/doi:10.1503/cmaj.181644/-/DC1). 4 The following patients (< 3%) were excluded from this substudy: those with prerandomization end-stage kidney disease (i.e., patients with an estimated glomerular filtration rate of < 15 mL/min/1.73 m 2 [calculated using the Chronic Kidney Disease Epidemiology Collaboration equation 14 ] or patients receiving dialysis), those missing a prerandomization serum creatinine measurement (which is needed to define acute kidney injury) and those who did not undergo surgery.
Interventions
Patients were randomly assigned to receive either intravenous methylprednisolone (250 mg at anesthetic induction and 250 mg at initiation of cardiopulmonary bypass) or matching placebo. Prior randomized trials suggested that this steroid regimen, compared with placebo, decreased plasma concentrations of inflammatory biomarkers, improved hemodynamic stability, and reduced the need for vasopressors in patients having cardiac surgery with cardiopulmonary bypass. 8 
Data sources
Research personnel at each site collected patient data from medical charts, hospital discharge notes and patient interviews. Preoperative serum creatinine levels were recorded in the 30-day period before surgery and the peak postoperative serum creatinine level was recorded in the 14-day period after surgery. Beginning on Mar. 1, 2012 (after receipt of substudy grant funding), centres began recording all postoperative serum creatinine measurements taken in routine care in the 14-day period after surgery for eligible patients. No data on urine output were collected given difficulties with the accurate measurement of urine output in the setting of international data collection.
Substudy outcomes
The primary outcome of postoperative acute kidney injury (prespecified when enrolment began in 2007) was defined as an increase in the serum creatinine concentration (from the pre operative value) of 0.3 mg/dL or greater (≥ 26.5 µmol/L) or 50% or greater within 14 days after surgery, or receipt of dialysis within 30 days after surgery.
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Prespecified secondary definitions of acute kidney injury To determine whether the primary results were robust, we examined 6 secondary definitions of acute kidney injury (comparing the peak postoperative serum creatinine concentration in the 14-day period after surgery to the preoperative value). 1. The primary definition of acute kidney injury or death within 48 hours after surgery (to account for the potential impact of early deaths on outcome ascertainment). 2. Stage 2 acute kidney injury or higher, defined as an increase in postoperative serum creatinine of 100% or greater, or an increase to an absolute value of 4.0 mg/dL or greater (≥ 353.6 µmol/L) (while meeting the primary definition), or receipt of dialysis within 30 days after surgery. 3. Stage 3 acute kidney injury, defined as an increase in postoperative serum creatinine of 200% or greater, or an increase to an absolute value of 4.0 mg/dL or greater (≥ 353.6 µmol/L) (while meeting the primary definition), or receipt of dialysis within 30 days after surgery. 4. Receipt of dialysis within 30 days after surgery. 5. Percentage change in serum creatinine, defined as [(peak postoperative serum creatinine -preoperative serum creatinine)/preoperative serum creatinine] × 100. 6. Absolute change in serum creatinine defined as peak postoperative serum creatinine -preoperative serum creatinine. In 2012, Kidney Disease Improving Global Outcomes published a guideline 15 defining acute kidney injury with an increase in serum creatinine of 0.3 mg/dL or greater (≥ 26.5 µmol/L) within 48 hours, or an increase of 50% or greater within 7 days. We examined this definition in a subsample of patients who were randomly assigned on or after Mar. 1, 2012 (when the study began recording all serum creatinine values measured during routine care). Acute kidney injury that was present on (i) at least 2 days and (ii) at least 3 days within 7 days after surgery was also examined in this subsample. 4 
Randomization procedures
Patients were randomly assigned (1:1) using a central 24-hour computerized randomization system. Patients were assigned to either intravenous methylprednisolone or placebo by block randomization with random block sizes of 2, 4 or 6, stratified by centre. The study drug was prepared and masked by local pharmacies at the study centres. Patients, health care providers, data collectors and outcome adjudicators were unaware of treatment allocation.
Sample size
We anticipated that at least 7000 patients enrolled in the main trial would be eligible for the kidney substudy, providing at least 90% power to detect a 10% RR reduction for the primary outcome of acute kidney injury (2-sided α = 0.05), assuming an incidence of 38% in the placebo group. With the inclusion of 7286 patients (97% of 7507 randomly assigned in the main trial), this substudy had 94% power to detect a 10% RR reduction in the primary outcome.
Statistical analysis
We conducted analyses using the intention-to-treat principle. Data were analyzed using SAS version 9.2. A modified Poisson regression model (accounting for centre) was used to estimate the RR and 95% confidence interval (CI) for acute kidney injury in patients randomly assigned to methylprednisolone versus placebo; a sandwich variance estimator was used to account for the effect of centre and to incorporate a robust error estimator in the modified Poisson regression approach for a binary response variable. 16, 17 We determined unadjusted and adjusted estimates. The adjusted models included 10 prespecified covariates: age, sex, left ventricular function less than 50%, diabetes, prerandomization medication use, estimated glomerular filtration rate less than 60 mL/min/1.73m 2 , surgery type and evidence of nonelective surgery. We used multiple imputation to impute missing data on left ventricular ejection fraction (a covariate; missing for 0.9%) and in a sensitivity analysis of acute kidney injury (missing for 0.8%); further details are provided in Appendices 2 and 3, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.181644/-/DC1. We estimated the adjusted percentage change and absolute change in postoperative serum creatinine using linear regression models. The risk of acute kidney injury in patients with preoperative chronic kidney disease (defined by an estimated glomerular filtration rate of < 60 mL/min/1.73 m 2 ) was examined by including an interaction term in the model.
We conducted 3 other prespecified analyses. First, the betweengroup difference in adherence was examined, where adherence was defined as the percentage of patients receiving the treatment as randomly assigned, and the percentage using nonstudy corticosteroids in the operating room and in the first 3 days after surgery. Second, the possibility of differential outcome ascertainment was assessed in the subgroup of patients who had multiple serum creatinine measurements within 7 days of surgery (those randomly assigned on or after Mar. 1, 2012) . Third, the primary analyses were repeated after excluding patients who underwent emergent or urgent surgery (defined based on preoperative use of inotropes, vasopressors, an intra-aortic balloon pump, or a ventricular assist device, or evidence of myocardial infarction in the 30 days before surgery).
Ethics approval
Ethics approval to conduct the trial was obtained at all participating centres, and all participants provided written informed consent before enrolment; SIRS was centrally coordinated at the Population Health Research Institute at McMaster University and Hamilton Health Sciences, Hamilton, Ontario. In some countries with more than 3 centres recruiting, a national coordinating office was responsible for obtaining the national regulatory approvals and coordinating research ethics application at each site. 11, 12 Excluded from kidney study n = 221
• End-stage kidney disease n = 116 • Did not have surgery n = 87 • Missing pre-randomization serum creatinine n = 18
Patients randomly assigned in SIRS trial (80 sites) and assessed for eligibility for kidney substudy n = 7507
Enrolled in the kidney substudy (79 sites) n = 7286
Randomly assigned to receive methylprednisolone n = 3647
• Received treatment as randomly assigned n = 3512
• No study drug given n = 104
• Only 1 dose of study drug given n = 27
• Received the wrong treatment kit n = 4
Randomly assigned to receive placebo n = 3639
• No study drug given n = 96
• Only 1 dose of study drug given n = 26
• Received the wrong treatment kit n = 5
• Received nonstudy steroids during surgery n = 104
• Received nonstudy steroids postoperatively n = 148
• Received nonstudy steroids during surgery n = 97
• Received nonstudy steroids postoperatively n = 151
Included in analysis of primary outcome n = 3639 Included in analysis of primary outcome n = 3647 
Results
Trial enrolment began on June 19, 2007 , and the last patient was randomly assigned on Dec. 19, 2013 . Of 7507 patients randomly assigned in the main trial, 7286 met the eligibly criteria for this substudy (3647 methylprednisolone and 3639 placebo) ( Figure 1 ). The median time from the prerandomization serum creatinine assessment to surgery was 2 (interquartile range 
Postoperative acute kidney injury
Postoperative acute kidney injury occurred in 1479 of 3647 patients (40.6%) in the methylprednisolone group and in 1426 of 3639 patients (39.2%) in the placebo group (unadjusted RR 1.03, 95% CI 0.98 to 1.09; adjusted RR 1.04, 95% CI 0.96 to 1.11) ( Table 2) . Results were consistent across 4 other categorical definitions of acute kidney injury (Table 2 ) and in sensitivity analyses using different methods to handle missing outcome data (Appendix 6, available at www.cmaj .ca/lookup/suppl/ doi:10.1503/cmaj.181644/-/DC1). The adjusted mean difference in the percentage change in serum creatinine was 0.02% (95% CI -3.7% to 3.7%), and the adjusted mean difference in the absolute change was -0.01 mg/dL (0.6 µmol/L), 95% CI -0.04 to 0.02 (Table 3 ). The RR of acute kidney injury did not differ significantly in patients with and without preoperative chronic kidney disease ( Figure 2 and Table 4 ). In the subsample of 4824 patients with serial postoperative serum creatinine assessments, postoperative acute kidney injury (serum creatinine threshold defined according to guidance from Kidney Disease Improving Global Outcomes) occurred in 832/2405 patients (35%) in the methylprednisolone group and in 819/2419 patients (34%) in the Table 5 ). The treatment was received as assigned for 96% in each group. Nonstudy corticosteroids were received in the operating room by 2.9% and 2.7% in the methylprednisolone versus placebo group, respectively, and by 4.1% in each group in the first 3 days after surgery. In the subsample of patients with serial postoperative serum creatinine measurements, 98% of each group had at least 1 measurement, and each group had a median of [5] [6] 
Interpretation
In this randomized controlled trial involving patients who underwent cardiopulmonary bypass surgery, allocation to perioperative methylprednisolone did not alter the risk of acute kidney injury. Results were consistent across several definitions of acute kidney injury, and in patients with preoperative chronic kidney disease.
This study provides reliable, generalizable effect estimates from a sample of more than 7000 patients recruited from 79 centres in 18 countries. The lower bound of the 95% CI of the treatment estimates suggests that clinically important benefits of perioperative steroids on the risk of acute kidney injury are unlikely. Although inflammatory markers were not measured in this study, we used the same steroid regimen that was used in the pilot study that resulted in decreased plasma concentrations of inflammatory biomarkers, improved hemodynamic stability and a reduced need for vasopressors. 8 Our findings are discordant with a post-hoc analysis of a similar but smaller trial (n = 4465) in which dexamethasone (1 mg/kg, maximum 100 mg) versus placebo significantly reduced the risk of in-hospital dialysis (10/2229 [0.4%] 5, 10 However, the wide CI and low number of dialysis events (33 v. 183 in our study) means this result is statistically fragile (i.e., the result would be statistically nonsignificant if 1 more event occurred in the intervention group). Note: ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CABG = coronary artery bypass graft, eGFR = estimated glomerular filtration rate, IABP = intra-aortic balloon pump, MI = myocardial infarction, SD = standard deviation, SIRS = Steroids in Cardiac Surgery, VAD = ventricular assist device. *All baseline characteristics (except surgical data) were assessed before randomization (surgical data [i.e., preoperative use of inotropes or vasopressors, or IABP or VAD, and surgery type] were assessed at the time of surgery; the median time from randomization to surgery was 17 [interquartile range hours; time of randomization was missing for all 483 pilot patients; time of surgery was missing for 2 patients from the main study). †All patients in the pilot study (methylprednisolone [n = 243] and placebo [n = 240]) were missing data on prerandomization body mass index, ethnicity, and prerandomization use of ACE inhibitors or ARBs (however, information on combined ACE/ARB use was available). Data on left ventricular ejection fraction were missing in 68 patients (methylprednisolone [n = 29], placebo [n = 39]). Data on the remaining variables were missing for < 2% of patients. For missing data on categorical variables, the condition/medication/procedure was considered absent; for calculating eGFR, patients missing ethnicity were assumed to be white. Pilot patients who answered "yes" to taking a statin or a nonstatin lipid-lowering agent were assumed to be taking a statin. ‡Unless stated otherwise. §Data on self-reported ethnic origin were collected and recorded by a research assistant using prespecified categories (black or white ethnic origin is needed for the calculation of eGFR). ¶Calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration equation). 14 **Evidence of nonelective surgery was defined by preoperative use of inotropes, vasopressors, an IABP or a VAD, or history of an MI in the 30 days before surgery. † †Surgery type "other" includes patients who had an aorta surgery (patch enlargement, Bentall procedure, ascending aortic replacement, arch replacement, and/or descending thoracic aortic replacement) or cardiac ablation surgery, or some type of "other cardiac procedure." Patients in this category may have had one of CABG or valve surgery, but not both; if a patient had both CABG and valve as well as aorta surgery and/or cardiac ablation surgery, they are included in the "CABG and valve" category.
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To understand the effect of corticosteroids on acute kidney injury better, we updated a previous meta-analysis of placebo-controlled trials involving adult patients undergoing cardiac surgery. 7 In these trials, acute kidney injury was usually defined as a 50% or greater increase in serum creatinine from the preoperative value or receipt of dialysis. The updated forest plot is shown in Appendix 9,  Note: CABG = coronary artery bypass grafting, CI = confidence interval. *A peak postoperative serum creatinine measurement was available for 99.1% of patients. Of 62 patients missing a peak postoperative value (31 in the methylprednisolone group and 31 in the placebo group), 2 received dialysis in the 30-day period after surgery and were coded as having acute kidney injury (1 in the methylprednisolone group and 1 in the placebo group). The remaining 60 patients were assumed to not have acute kidney injury; of these 60 patients, 50 (83.3%) died on the day of surgery or on day 1 or 2 after surgery (27/30 [90.0%] in the methylprednisolone group and 23/30 [76.7%] in the placebo group). †A modified Poisson regression model was used without adjustment for covariates or accounting for centre. ‡Adjusted for 10 prespecified covariates using a generalized estimating equation approach accounting for centre: age (yr); sex; left ventricular function < 50%; diabetes; preoperative estimated glomerular filtration rate < 60 mL/min/1.73m 2 ; prerandomization use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins or diuretics; surgery type (isolated valve [referent], isolated CABG, CABG and valve, or other); and evidence of nonelective surgery (defined as preoperative use of inotropes or vasopressors, preoperative use of an intra-aortic balloon pump or ventricular assist device, or evidence of myocardial infarction in the 30 days before surgery). §Defined as an increase in serum creatinine concentration (from the preoperative value) of 0.3 mg/dL or more (≥ 26.5 µmol/L) or 50% or more in the 14-day period after surgery, or receipt of dialysis in the 30-day period after surgery. ¶Met the primary definition of acute kidney injury or died within 48 hours of surgery. This was examined to account for the potential impact of early deaths on the ascertainment of acute kidney injury; early deaths occurred in 48 (1.3%) patients in the methylprednisolone group and in 47 (1.3%) patients in the placebo group. **Defined as an increase in postoperative serum creatinine of 100% or more from the preoperative value or an increase to an absolute value of 4.0 mg/dL or more (≥ 353.6 µmol/L) (while meeting the primary definition) within 14 days of surgery, or (iii) receipt of dialysis within 30 days of surgery. † †Defined as an increase in postoperative serum creatinine of 200% or more from the preoperative value or an increase to an absolute value of 4.0 mg/dL or more (≥ 353.6 µmol/L) (while meeting the primary definition) within 14 days of surgery, or receipt of dialysis within 30 days of surgery. ‡ ‡Receipt of dialysis in the 30 days after surgery. In patients who received acute dialysis, the median increase in serum creatinine concentration from the preoperative to the postoperative value was 1.7 (interquartile range 1. Figure 2 : Effect of methylprednisolone versus placebo on the risk of acute kidney injury: subgroup analysis by preoperative chronic kidney disease. Note: CI = confidence interval, RR = relative risk. *Adjusted for 9 prespecified covariates: age (years); sex; left ventricular function < 50%; diabetes; prerandomization use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, or diuretics; surgery type (isolated valve [referent] , isolated coronary artery bypass grafting [CABG] , CABG and valve, or other); and evidence of nonelective surgery (defined as preoperative use of inotropes or vasopressors, preoperative use of an intra-aortic balloon pump or ventricular assist device, or evidence of myocardial infarction in the 30 days before surgery). †Chronic kidney disease was defined as a preoperative estimated glomerular filtration rate < 60 mL/min/1.73m
2 . The RR of acute kidney injury with methylprednisolone versus placebo was not statistically significantly different in those with versus without preoperative chronic kidney disease (p = 0.3 for interaction). 
Limitations
Although serum creatinine measurement is part of routine care after cardiac surgery, sole reliance on routine measures could introduce ascertainment bias. For example, if methylprednisolone altered the incidence of myocardial infarction or other events, this could alter the frequency of serum creatinine assessment and influence the detection of acute kidney injury. Also, multiple measures of serum creatinine are preferred for the accurate assessment of kidney function. To address these concerns, we examined several definitions of acute kidney injury, and we collected multiple postoperative serum creatinine measurements in a subsample of 4824 patients (66%). Results were consistent across all sensitivity analyses, and no between-group differences in the frequency of serum creatinine measurements were observed. Results were also consistent after excluding patients having urgent surgery (baseline concentrations of serum creatinine may have been unstable in these patients).
Conclusion
Prophylactic intravenous steroids administered in the operating room did not alter the risk of acute kidney injury in patients with a moderate-to-high risk of perioperative death who had cardiac surgery with cardiopulmonary bypass. Strategies focusing on other noninflammatory contributors of peri operative acute kidney injury, such as improving renal perfusion and decreasing hemolysis 20 warrant future consideration. †A modified Poisson regression model was used without adjustment for covariates or accounting for centre. ‡Adjusted for 10 prespecified covariates: age (yr); sex; left ventricular function < 50%; diabetes; preoperative estimated glomerular filtration rate < 60 mL/min/1.73m 2 ; prerandomization use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, or diuretics; surgery type (isolated valve [referent] , isolated coronary artery bypass grafting [CABG] , CABG and valve, or other); and evidence of nonelective surgery (defined as preoperative use of inotropes or vasopressors, preoperative use of an intra-aortic balloon pump or ventricular assist device, or evidence of myocardial infarction in the 30 days before surgery).
§Defined as an increase in the serum creatinine concentration (from the preoperative value) of ≥ 0.3 mg/dL [≥ 26.5 µmol/L] within 48 hours of surgery, or ≥ 50% within 7 days of surgery, or receipt of dialysis within 30 days after surgery. Results were similar in a sensitivity analyses that imputed missing postoperative creatinine data with a peak value obtained in the first 14 days after surgery (available for 50 of the 89 patients missing outcome data for the KIDIGO guideline definition): adjusted relative risk 1.02 (95% CI 0.93 to 1.12) . ¶Defined as an increase in serum creatinine concentration (from the preoperative value) of ≥ 0.3 mg/dL [≥ 26.5 µmol/L] or ≥ 50%, evident on at least 2 separate days within 7 days of surgery, or receipt of dialysis within 30 days after surgery. **Defined as an increase in serum creatinine concentration (from the preoperative value) of ≥ 0.3 mg/dL [≥ 26.5 µmol/L] or ≥ 50%, evident on at least 3 separate days within 7 days of surgery, or receipt of dialysis within 30 days after surgery.
